Breaking News


Once-weekly etanercept improves patient-reported outcomes in patients with mild-moderate psoriasis


A 12-week, randomized, double-blind, placebo-controlled study evaluated the quality of life (QoL) and patient-reported outcomes (PROs) in psoriasis patients receiving once-weekly etanercept 50 mg (n = 96) or placebo (n = 46).This was followed by a 12-week open-label extension in patients with moderate-severe psoriasis. QoL assessments comprised the Dermatology Life Quality Inventory (DLQI), the EuroQoL-5D (EQ-5D) and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale. At week 12, statistical (P < 0.05) and clinical improvement was produced in the etanercept group on the DLQI and EQ-5D but not FACIT-F scales. After 24 weeks of etanercept, the mean DLQI score improved slightly while EQ-5D and FACIT-F scores were close to the population ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list